A Phase 2 interventional study of IMVT-1402 and Placebo in Subacute Cutaneous Lupus Erythematosus and Chronic Cutaneous Lupus Erythematosus, sponsored by Immunovant Sciences GmbH. Active, not recruiting at 86 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-28.
Sponsored by Immunovant Sciences GmbH · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Lupus Erythematosus, Cutaneous with a site in United States — 10 open to participants now, 16 under way, 7 of them phase 3. Lupus Erythematosus, Cutaneous · United States.
Among the 39 studies in Lupus Erythematosus, Cutaneous with a site in United States, this one is the 15th largest by planned enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2025, is one of 15 in phase 2, reaches primary completion later than 1 of the 15 other live ones, and was the 33rd registered.
67 studies on the registry are indexed under Lupus Erythematosus, Cutaneous; 18 are open to participants now.
Browse Lupus Erythematosus, Cutaneous studies →10 of the 39 studies in Lupus Erythematosus, Cutaneous with a site in United States are open now. Recruiting first, the newest first:
Beeline Medicines Corporation · Sites in United States
Ages 16+
EMD Serono Research & Development Institute, Inc. · Sites in United States
Ages 18–76
Victoria Werth · Sites in United States
Ages 18+
EMD Serono Research & Development Institute, Inc. · Sites in United States, Australia, Belgium and 17 more countries
Ages 18–75
EMD Serono Research & Development Institute, Inc. · Sites in United States, Australia, Belgium and 17 more countries
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Lupus Erythematosus, Cutaneous studies recruiting now, 4 (33%) set no upper age limit and 7 (58%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 18 · Phase 3 7
First in 2006; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 56 is above the median of 32 across 57 interventional studies indexed under Lupus Erythematosus, Cutaneous.
Median enrollment 46 across the 34 interventional studies, 77 across the 5 observational. Of the 23 that completed or were terminated, 11 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 39 have an industry lead sponsor. The 10 most frequent:
Immunovant Sciences GmbH is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 5 (45%) have results posted.
Immunovant Sciences GmbH has 1 study filed under Lupus Erythematosus, Cutaneous — fewer than ten, so there is no comparison to draw.
3 of the studies in Lupus Erythematosus, Cutaneous with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07260877Ventus Therapeutics U.S., Inc.A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus | 2026-12 |
| NCT06625671DualityBio Inc.A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants | 2027-06-30 |
| NCT06661213Northwestern UniversityTapinarof for Cutaneous Lupus Erythematosus | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies in Lupus Erythematosus, Cutaneous with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of IMVT-1402 in participants with Cutaneous Lupus Erythematosus.
The study will consist of 3 periods:
Period 1: eligible participants will be randomized 1:1 to IMVT-1402 Dose 1 or placebo SC QW for 12 weeks.
Period 2: participants who completed Period 1 will receive IMVT-1402 Dose 1 SC QW for 14 weeks.
Period 3: after completion of Period 2, participants will be re-randomized 1:1 to blinded IMVT-1402 Dose 1 or Dose 2 SC QW for 26 weeks.
The total study duration per participant is approximately 61 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Matching placebo for 12 weeks in Period 1
Drug: Placebo
* Period 1: IMVT-1402 Dose 1 SC QW for 12 weeks * Period 2: IMVT-1402 Dose 1 SC QW for 14 weeks * Period 3: IMVT-1402 Dose 1 or Dose 2 SC QW for 26 weeks
Drug: IMVT-1402
Dose 1 or Dose 2 SC QW
Matching Placebo SC QW
Percent change from Period 1 Baseline in Cutaneous Lupus Erythematosus Disease area and Severity Index activity (CLASI-A) score at Week 12
The CLASI-A score represents the overall severity of cutaneous lupus erythematosus (CLE) dermatologic involvement. It is used to assess the activity of mucocutaneous lesions in patients with lupus. The score ranges from 0 (no active lesions) to a maximum of 70. Values between 1 and 9 indicate mild inflammation, 10 to 20 indicate moderate inflammation, and 21 or higher indicate severe inflammation.
Time frame: Baseline (Day 1) and Week 12
Proportion of participants who have a reduction in CLASI-A score of ≥ 5 points from Period 1 Baseline at Week 12
Time frame: Baseline (Day 1) and Week 12
Proportion of participants who have a reduction in CLASI-A score of ≥ 50% from Period 1 Baseline at Week 12
Time frame: Baseline (Day 1) and Week 12
Proportion of participants who have a reduction in CLASI-A score of ≥ 70% from Period 1 Baseline at Week 12
Time frame: Baseline (Day 1) and Week 12
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Oct 2026, 20 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Imeroprubart
Lupus Erythematosus, Cutaneous →
Immunovant Sciences GmbH